Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Biogen Inc. said Thursday that it has settled a lawsuit with Berlex Laboratories Inc. over a patent infringement claim related to a drug used to treat multiple sclerosis. Biogen’s flagship drug, Avonex, is a human beta interferon product. So is Betaseron, which is marketed by Berlex. Both have been approved by the U.S. Food and Drug Administration for the treatment of multiple sclerosis. In August 2000, a federal judge in Boston ruled that Cambridge, Mass.-based Biogen did not infringe on patents owned by New Jersey-based Berlex Laboratories. Berlex appealed that ruling. That appeal is still pending. Under the settlement agreement, Biogen will pay Berlex $20 million and receive a fully paid up, royalty-free, non-exclusive license under the patents held by Berlex. A second and final payment from Biogen to Berlex will also be made if an appeals court reverses the lower court’s ruling in favor of Biogen. The agreement calls for a final payment of $55 million if the 1st U.S. Circuit Court of Appeals rules against Biogen and returns the case to U.S. District Court. If the appeals court completely reverses the decision favoring Biogen, then Biogen would have to make a final payment of $230 million. Biogen spokeswoman Kathleen O’Donnell said the company believes both those scenarios are unlikely. “The rulings of the court … are leading us to believe that the $20 million will be the exact payment,” she said. Peter Kellogg, Biogen’s chief financial officer, said the company wanted to settle the case, which has dragged on for almost six years. “We are the worldwide leader of Avonex; the business is growing very rapidly. [The company felt] this has gone on long enough and we should just resolve it and move on,” he said. As part of the settlement, the companies agreed not to pursue further litigation over the patents. Biogen has taken a $20 million charge against earnings in its fourth quarter 2001 to cover the costs of the settlement. Biogen reported earnings of $58.9 million, or 39 cents per share, in the fourth quarter, including the $20 million charge, compared with $71.8 million, or 47 cents per share, in the same period a year ago. In afternoon trading on the New York Stock Exchange, Biogen shares rose 25 cents to $55.22. Copyright 2002 Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.